rs774116060

Variant summary

Our verdict is Benign. The variant received -16 ACMG points: 0P and 16B. BP4_StrongBP6_Very_StrongBS2

The NM_021098.3(CACNA1H):​c.6718G>A​(p.Ala2240Thr) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000648 in 1,604,084 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★). Synonymous variant affecting the same amino acid position (i.e. A2240A) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.000033 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000068 ( 0 hom. )

Consequence

CACNA1H
NM_021098.3 missense

Scores

1
1
17

Clinical Significance

Likely benign criteria provided, multiple submitters, no conflicts B:2

Conservation

PhyloP100: -1.37

Publications

0 publications found
Variant links:
Genes affected
CACNA1H (HGNC:1395): (calcium voltage-gated channel subunit alpha1 H) This gene encodes a T-type member of the alpha-1 subunit family, a protein in the voltage-dependent calcium channel complex. Calcium channels mediate the influx of calcium ions into the cell upon membrane polarization and consist of a complex of alpha-1, alpha-2/delta, beta, and gamma subunits in a 1:1:1:1 ratio. The alpha-1 subunit has 24 transmembrane segments and forms the pore through which ions pass into the cell. There are multiple isoforms of each of the proteins in the complex, either encoded by different genes or the result of alternative splicing of transcripts. Alternate transcriptional splice variants, encoding different isoforms, have been characterized for the gene described here. Studies suggest certain mutations in this gene lead to childhood absence epilepsy (CAE). [provided by RefSeq, Jul 2008]
CACNA1H Gene-Disease associations (from GenCC):
  • hyperaldosteronism, familial, type IV
    Inheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
  • childhood absence epilepsy
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • epilepsy, childhood absence, susceptibility to, 6
    Inheritance: AD Classification: LIMITED Submitted by: G2P, Labcorp Genetics (formerly Invitae)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -16 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.030469418).
BP6
Variant 16-1220650-G-A is Benign according to our data. Variant chr16-1220650-G-A is described in ClinVar as Likely_benign. ClinVar VariationId is 460176.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BS2
High AC in GnomAd4 at 5 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CACNA1HNM_021098.3 linkc.6718G>A p.Ala2240Thr missense_variant Exon 35 of 35 ENST00000348261.11 NP_066921.2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CACNA1HENST00000348261.11 linkc.6718G>A p.Ala2240Thr missense_variant Exon 35 of 35 1 NM_021098.3 ENSP00000334198.7
CACNA1HENST00000569107.6 linkc.6733G>A p.Ala2245Thr missense_variant Exon 34 of 34 1 ENSP00000454990.2
CACNA1HENST00000711493.1 linkc.6703G>A p.Ala2235Thr missense_variant Exon 34 of 34 ENSP00000518778.1
CACNA1HENST00000565831.7 linkc.6700G>A p.Ala2234Thr missense_variant Exon 34 of 34 1 ENSP00000455840.1
CACNA1HENST00000711450.1 linkc.6700G>A p.Ala2234Thr missense_variant Exon 35 of 35 ENSP00000518762.1
CACNA1HENST00000564231.6 linkc.6685G>A p.Ala2229Thr missense_variant Exon 35 of 35 1 ENSP00000457555.2
CACNA1HENST00000638323.1 linkc.6679G>A p.Ala2227Thr missense_variant Exon 35 of 35 5 ENSP00000492267.1
CACNA1HENST00000562079.6 linkc.6667G>A p.Ala2223Thr missense_variant Exon 34 of 34 1 ENSP00000454581.2
CACNA1HENST00000711438.1 linkc.6661G>A p.Ala2221Thr missense_variant Exon 34 of 34 ENSP00000518754.1
CACNA1HENST00000637236.3 linkn.*2637G>A non_coding_transcript_exon_variant Exon 34 of 34 5 ENSP00000492650.2
CACNA1HENST00000639478.1 linkn.*1766G>A non_coding_transcript_exon_variant Exon 35 of 35 5 ENSP00000491945.1
CACNA1HENST00000640028.1 linkn.*4536G>A non_coding_transcript_exon_variant Exon 35 of 35 5 ENSP00000491488.1
CACNA1HENST00000711442.1 linkn.*6162G>A non_coding_transcript_exon_variant Exon 33 of 34 ENSP00000518758.1
CACNA1HENST00000711448.1 linkn.*1659G>A non_coding_transcript_exon_variant Exon 36 of 36 ENSP00000518760.1
CACNA1HENST00000711449.1 linkn.*1577G>A non_coding_transcript_exon_variant Exon 35 of 35 ENSP00000518761.1
CACNA1HENST00000711451.1 linkn.*2297G>A non_coding_transcript_exon_variant Exon 36 of 36 ENSP00000518763.1
CACNA1HENST00000711452.1 linkn.*1385G>A non_coding_transcript_exon_variant Exon 36 of 36 ENSP00000518764.1
CACNA1HENST00000711453.1 linkn.*1352G>A non_coding_transcript_exon_variant Exon 36 of 36 ENSP00000518765.1
CACNA1HENST00000711484.1 linkn.*632G>A non_coding_transcript_exon_variant Exon 34 of 35 ENSP00000518773.1
CACNA1HENST00000711486.1 linkn.6718G>A non_coding_transcript_exon_variant Exon 35 of 37 ENSP00000518775.1
CACNA1HENST00000711487.1 linkn.6685G>A non_coding_transcript_exon_variant Exon 35 of 36 ENSP00000518776.1
CACNA1HENST00000711488.1 linkn.*1834G>A non_coding_transcript_exon_variant Exon 35 of 35 ENSP00000518777.1
CACNA1HENST00000711482.1 linkc.*197G>A 3_prime_UTR_variant Exon 36 of 36 ENSP00000518771.1
CACNA1HENST00000711485.1 linkc.*197G>A 3_prime_UTR_variant Exon 35 of 35 ENSP00000518774.1
CACNA1HENST00000711455.1 linkc.*197G>A 3_prime_UTR_variant Exon 36 of 36 ENSP00000518768.1
CACNA1HENST00000711483.1 linkc.*632G>A 3_prime_UTR_variant Exon 35 of 35 ENSP00000518772.1
CACNA1HENST00000711456.1 linkc.*632G>A 3_prime_UTR_variant Exon 34 of 34 ENSP00000518769.1
CACNA1HENST00000637236.3 linkn.*2637G>A 3_prime_UTR_variant Exon 34 of 34 5 ENSP00000492650.2
CACNA1HENST00000639478.1 linkn.*1766G>A 3_prime_UTR_variant Exon 35 of 35 5 ENSP00000491945.1
CACNA1HENST00000640028.1 linkn.*4536G>A 3_prime_UTR_variant Exon 35 of 35 5 ENSP00000491488.1
CACNA1HENST00000711442.1 linkn.*6162G>A 3_prime_UTR_variant Exon 33 of 34 ENSP00000518758.1
CACNA1HENST00000711448.1 linkn.*1659G>A 3_prime_UTR_variant Exon 36 of 36 ENSP00000518760.1
CACNA1HENST00000711449.1 linkn.*1577G>A 3_prime_UTR_variant Exon 35 of 35 ENSP00000518761.1
CACNA1HENST00000711451.1 linkn.*2297G>A 3_prime_UTR_variant Exon 36 of 36 ENSP00000518763.1
CACNA1HENST00000711452.1 linkn.*1385G>A 3_prime_UTR_variant Exon 36 of 36 ENSP00000518764.1
CACNA1HENST00000711453.1 linkn.*1352G>A 3_prime_UTR_variant Exon 36 of 36 ENSP00000518765.1
CACNA1HENST00000711484.1 linkn.*632G>A 3_prime_UTR_variant Exon 34 of 35 ENSP00000518773.1
CACNA1HENST00000711488.1 linkn.*1834G>A 3_prime_UTR_variant Exon 35 of 35 ENSP00000518777.1
CACNA1HENST00000621827.2 linkn.6121+597G>A intron_variant Intron 35 of 36 6 ENSP00000518766.1

Frequencies

GnomAD3 genomes
AF:
0.0000329
AC:
5
AN:
151996
Hom.:
0
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000589
Gnomad OTH
AF:
0.000478
GnomAD2 exomes
AF:
0.000130
AC:
29
AN:
223874
AF XY:
0.000153
show subpopulations
Gnomad AFR exome
AF:
0.0000795
Gnomad AMR exome
AF:
0.000428
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.000396
Gnomad NFE exome
AF:
0.0000617
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000682
AC:
99
AN:
1452088
Hom.:
0
Cov.:
35
AF XY:
0.0000707
AC XY:
51
AN XY:
721728
show subpopulations
African (AFR)
AF:
0.0000603
AC:
2
AN:
33146
American (AMR)
AF:
0.000322
AC:
14
AN:
43416
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
25836
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39346
South Asian (SAS)
AF:
0.0000117
AC:
1
AN:
85656
European-Finnish (FIN)
AF:
0.000273
AC:
14
AN:
51368
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5570
European-Non Finnish (NFE)
AF:
0.0000605
AC:
67
AN:
1107794
Other (OTH)
AF:
0.0000167
AC:
1
AN:
59956
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.499
Heterozygous variant carriers
0
6
12
18
24
30
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
4
8
12
16
20
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0000329
AC:
5
AN:
151996
Hom.:
0
Cov.:
33
AF XY:
0.0000135
AC XY:
1
AN XY:
74214
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
41378
American (AMR)
AF:
0.00
AC:
0
AN:
15280
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3472
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5154
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4822
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10618
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
316
European-Non Finnish (NFE)
AF:
0.0000589
AC:
4
AN:
67954
Other (OTH)
AF:
0.000478
AC:
1
AN:
2092
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.475
Heterozygous variant carriers
0
1
1
2
2
3
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00
Hom.:
0
Bravo
AF:
0.0000491
ExAC
AF:
0.000119
AC:
14

ClinVar

Significance: Likely benign
Submissions summary: Benign:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Inborn genetic diseases Benign:1
Jan 19, 2025
Ambry Genetics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Idiopathic generalized epilepsy;C4310756:Hyperaldosteronism, familial, type IV Benign:1
Nov 21, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.065
BayesDel_addAF
Benign
-0.52
T
BayesDel_noAF
Benign
-0.65
CADD
Benign
0.16
DANN
Benign
0.49
DEOGEN2
Benign
0.13
T;.;.;.
Eigen
Benign
-1.7
Eigen_PC
Benign
-1.8
FATHMM_MKL
Benign
0.0032
N
LIST_S2
Benign
0.54
T;T;T;.
M_CAP
Pathogenic
0.60
D
MetaRNN
Benign
0.030
T;T;T;T
MetaSVM
Benign
-1.0
T
MutationAssessor
Benign
0.41
N;.;.;.
PhyloP100
-1.4
PrimateAI
Uncertain
0.54
T
PROVEAN
Benign
-0.53
N;.;N;N
REVEL
Benign
0.047
Sift
Benign
1.0
T;.;T;T
Sift4G
Benign
0.26
T;.;T;T
Polyphen
0.0020
B;.;B;B
Vest4
0.017
MutPred
0.096
Gain of phosphorylation at A2240 (P = 0.0209);.;.;.;
MVP
0.44
ClinPred
0.016
T
GERP RS
-3.6
Varity_R
0.035
gMVP
0.056
Mutation Taster
=95/5
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs774116060; hg19: chr16-1270650; COSMIC: COSV105094275; COSMIC: COSV105094275; API